Sr. Associate Scientist, In Vivo Pharmacology

Senior Director, Regulatory Affairs

Medical Director/ Senior Director , Drug Safety & Pharmacovigilance

Senior Principal Software Engineer

Associate Director / Director, Clinical Science

Director, Drug Product Development

Sr. Scientist, Discovery DMPK 

Senior Medical Director/Associate Vice President, Clinical Development

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

FogPharma is developing treatments for currently undruggable disease targets. Many drugs can be classified as monoclonal antibodies that cannot access the cell interior or as small molecules that lack specificity for interior targets. FogPharma is focusing on a new class of drugs - Helicon polypeptides - that combine the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. The polypeptides designed by FogPharma have an alpha helical shape, which confers unique drug-like properties and greater stability. FogPharma evaluates thousands of new peptides weekly in biochemical and cell-based assays to select hits to develop. FogPharma’s lead product, FOG-001, targets β-catenin, which is commonly overactive in cancer. 

<p>FogPharma is developing treatments for currently undruggable disease targets. Many drugs can be classified as monoclonal antibodies that cannot access the cell interior or as small molecules that lack specificity for interior targets. FogPharma is focusing on a new class of drugs - Helicon polypeptides - that combine the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. The polypeptides designed by FogPharma have an alpha helical shape, which confers unique drug-like properties and greater stability. FogPharma evaluates thousands of new peptides weekly in biochemical and cell-based assays to select hits to develop. FogPharma’s lead product, FOG-001, targets β-catenin, which is commonly overactive in cancer. </p>


Find a biotech startup job.